[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369040-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-369040-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","efficacy-safety-and-biomarkers-of-neoadjuvant-trastuzumab-and-pertuzumab-combined-with-chemotherapy-in-chinese-patients-with-her2-positive-breast-cancer-multicenter-retrospective-cohort-study","Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer - Multicenter retrospective cohort study","","A multicenter retrospective real-world study assessed the efficacy, safety, and biomarker associations of neoadjuvant trastuzumab plus pertuzumab with different chemotherapy regimens in Chinese patients with HER2-positive breast cancer. Data from 557 patients treated from January 2019 to December 2021 across 15 institutions were analyzed using propensity score overlap weighting. Primary outcome was total pathological complete response (tpCR). Dual HER2-targeted therapy showed high tpCR rates with largely grade 1–2 adverse events and no reported fatal toxicities.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-safety-and-biomarkers-of-neoadjuvant-trastuzumab-and-pertuzumab-combined-with-chemotherapy-in-chinese-patients-with-her2-positive-breast-cancer-multicenter-retrospective-cohort-study/369040/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-safety-and-biomarkers-of-neoadjuvant-trastuzumab-and-pertuzumab-combined-with-chemotherapy-in-chinese-patients-with-her2-positive-breast-cancer-multicenter-retrospective-cohort-study/369040.png","ImageObject",300,407,{"name":42,"@type":43},"CatatanPagi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary endpoint used to evaluate treatment efficacy?","Question",{"text":63,"@type":64},"The primary endpoint was total pathological complete response (tpCR), defined as absence of invasive disease in both the breast and axillary lymph nodes (ypT0/is, ypN0).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped by chemotherapy regimen?",{"text":68,"@type":64},"Patients were divided into three regimen groups: EC-THP, TCbHP, and THP, based on combinations of epirubicin or docetaxel/paclitaxel protein-bound with carboplatin as applicable, plus trastuzumab and pertuzumab.",{"name":70,"@type":61,"acceptedAnswer":71},"Did the different chemotherapy regimens lead to differences after propensity score weighting?",{"text":72,"@type":64},"After propensity score overlap weighting, no significant differences were observed among the three regimen groups in tpCR, bpCR, or apCR.",{"name":74,"@type":61,"acceptedAnswer":75},"Which safety findings were most common?",{"text":76,"@type":64},"Most adverse events were grade 1–2. The most common included anemia (254/557, 45.6%), leukopenia (147/557, 26.4%), and reduced ejection fraction (99/421, 23.4%), and no fatal toxicities were reported.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},369040,1790704414,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Retrospective Cohort Study  \nEfficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study  \nXiaowei Qi, MDa ,*, Hong Hu, MDb , Pengfei Qiu, MDc , Wenlin Chen, MDd , Xiaochun Wang, MDe , Qiyun Shi, MDf, Yan Xu, MDg , Shu Liu, MDh , Yanman Fang, MSi , Taolang Li, MDj , Jia Ming, MDk , Sihai Zhou, MDl , Fan Chai, MDm , Yueyang Liang, MSn , Yuanming Fan, MDo , Peng Tang, MDa , Li Chen, MDa , Shushu Wang, MDa , Jun Jiang, MDa , Mengyuan Wang, MSp , Yi Zhang, MDa ,*, Jianyun Nie, MDd ,*, Yongsheng Wang, MDc ,*  \nObjective: This multicenter real-world study aimed to evaluate the efficacy, safety, and neoadjuvant trastuzumab and pertuzumab combined with different chemotherapy regimens in Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods: A retrospective analysis was conducted on 557 patients treated at 15 institutions in China between January 2019 and December 2021. Patients were divided into three groups based on chemotherapy regimens: EC-THP (epirubicin, cyclophosphamide, docetaxel/paclitaxel protein-bound, trastuzumab, pertuzumab), TCbHP (docetaxel/paclitaxel protein-bound, carboplatin, trastuzumab, pertuzumab), and THP (docetaxel/paclitaxel protein-bound, trastuzumab, pertuzumab) .The primary endpoint was total pathological complete response (tpCR), defined as the absence of invasive disease in both the breast and axillary lymph nodes (ypT0/is, ypN0) . Secondary endpoints included axillary pCR (ypN0), breast pCR (ypT0/is), and safety. Propensity score overlap weighting was applied to minimize confounding factors.  \nResults: Of the 557 patients included in the study, 341 (61 .2%) achieved tpCR. The tpCR rate was significantly higher in the HER2-positive hormone receptor (HR)-negative group (183/242 patients, 75.6%) than in the HER2-positive HR-positive group (158/315 patients, 50.2%, P \u003C 0.001), as well as bpCR was achieved in 188/241 patients (77 .7%) in the HER2-positive HR-negative group compared to 164/315 patients (52 . 1%) in the HER2-positive HR-positive group (P \u003C 0.001), and apCR was achieved in 214/242 patients (88 .4%) vs. 240/315 patients (76 .2%), respectively (P \u003C 0.001) . After applying propensity score overlap weighting, no significant differences were observed among the three treatment regimen groups intpCR (68 .4% vs. 63.0% vs. 54.5%, P = 0. 116), bpCR (71 .3% vs. 64.0% vs. 59.6%, P = 0. 198), or apCR (80 .2% vs. 84.4% vs. 73.9%, P = 0. 173) . Gene analysis suggested favorable tpCR trends in patients with TP53, ERBB2, MYC, or CCND1 alterations, though not statistically significant. Most adverse events were grades 1–2, with anemia (254/557, 45 .6%), leukopenia (147/557, 26 .4%), and reduced ejection fraction (99/421, 23 .4%) being the most common. No fatal toxicities were reported.  \nConclusions: Trastuzumab and pertuzumab combined with different chemotherapy regimens demonstrated high tpCR rates and manageable safety in HER2-positive breast cancer, particularly in HER2-positive HR-negative patients. The study supports the real-world efficacy of dual HER2-targeted neoadjuvant therapy, though further validation of biomarkers and long-term outcomes is needed.  \nKeywords: HER2-positive breast cancer, neoadjuvant chemotherapy, pathological complete response, pertuzumab, trastuzumab  \naDepartment of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, bDepartment of Breast and Thyroid Surgery, Shenzhen People’s Hospital, Shenzhen, Guangdong, China, cBreast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China, dThird Department of Breast Surgery, Peking University Cancer Hospital Yunan, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, eDepartment of Breast Surgery, Affiliated Hospital of Hebei Un","cbCaialWrLRejRn3","https://ap.wps.com/l/cbCaialWrLRejRn3","pdf",652658,14,"English","# Objective\n# Methods\n## Study design and endpoints\n# Results\n# Safety and biomarkers\n# Conclusions","[{\"question\":\"What was the primary endpoint used to evaluate treatment efficacy?\",\"answer\":\"The primary endpoint was total pathological complete response (tpCR), defined as absence of invasive disease in both the breast and axillary lymph nodes (ypT0/is, ypN0).\"},{\"question\":\"How were patients grouped by chemotherapy regimen?\",\"answer\":\"Patients were divided into three regimen groups: EC-THP, TCbHP, and THP, based on combinations of epirubicin or docetaxel/paclitaxel protein-bound with carboplatin as applicable, plus trastuzumab and pertuzumab.\"},{\"question\":\"Did the different chemotherapy regimens lead to differences after propensity score weighting?\",\"answer\":\"After propensity score overlap weighting, no significant differences were observed among the three regimen groups in tpCR, bpCR, or apCR.\"},{\"question\":\"Which safety findings were most common?\",\"answer\":\"Most adverse events were grade 1–2. The most common included anemia (254/557, 45.6%), leukopenia (147/557, 26.4%), and reduced ejection fraction (99/421, 23.4%), and no fatal toxicities were reported.\"}]","Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer - Multicenter retrospective cohort study | PDF",1790180308,35,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a2dba328a4476951859fdb99848d95e.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0264d2aa0c7e4648a7177d098ec75ccd.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3a408ecc12a11029efb93d035cec9fa.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbbb262528713132cbdb915bdf0c14b0.webp",980,1306]